Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Nature ; 2024 Feb 04.
Article in English | MEDLINE | ID: mdl-38311640
2.
Br J Cancer ; 124(4): 805-816, 2021 02.
Article in English | MEDLINE | ID: mdl-33214683

ABSTRACT

BACKGROUND: Understanding the pathways that drive adrenocortical carcinoma (ACC) is essential to the development of more effective therapies. This study investigates the role of the transcription factor HOXB9 and other HOX factors in ACC and its treatment. METHODS: We used transgenic mouse models to determine the role of Hoxb9 in adrenal tumour development. Patient transcriptomic data was analysed for the expression of HOX genes and their association with disease. Drug response studies on various adrenocortical models were done to establish novel therapeutic options. RESULTS: Our human ACC dataset analyses showed high expression of HOXB9, and other HOX factors, are associated with poorer prognosis. Transgenic overexpression of Hoxb9 in the adrenal cortex of mice with activated Ctnnb1 led to larger adrenal tumours. This phenotype was preferentially observed in male mice and was characterised by more proliferating cells and an increase in the expression of cell cycle genes, including Ccne1. Adrenal tumour cells were found to be dependent on HOX function for survival and were sensitive to a specific peptide inhibitor. CONCLUSIONS: These studies show Hoxb9 can promote adrenal tumour progression in a sex-dependent manner and have identified HOX factors as potential drug targets, leading to novel therapeutic approaches in ACC.


Subject(s)
Adrenal Cortex Neoplasms/drug therapy , Adrenal Cortex Neoplasms/genetics , Adrenocortical Carcinoma/drug therapy , Adrenocortical Carcinoma/genetics , Homeodomain Proteins/genetics , Peptides/pharmacology , Adrenal Cortex Neoplasms/pathology , Adrenocortical Carcinoma/pathology , Animals , Cell Proliferation/genetics , Female , Gene Expression , Homeodomain Proteins/biosynthesis , Humans , Male , Mice , Mice, Transgenic , Molecular Targeted Therapy , Peptides/genetics
3.
J Infect Dis ; 220(220 Suppl 3): S108-S115, 2019 10 08.
Article in English | MEDLINE | ID: mdl-31593598

ABSTRACT

The World Health Organization's (WHO) "End TB" strategy calls for development and implementation of novel tuberculosis (TB) diagnostics. Sputum-based diagnostics are challenging to implement and often less sensitive in high-priority populations. Nonsputum, biomarker-based tests may facilitate TB testing at lower levels of the healthcare system, accelerate treatment initiation, and improve outcomes. We provide guidance on the design of diagnostic accuracy studies evaluating nonsputum, biomarker-based tests within the context of WHO's target product profile for such tests. Study designs should account for the intended use when choosing the study population, setting, and reference standards. Although adults with respiratory symptoms may be an initial target population, other high-priority populations regardless of symptoms-including people living with human immunodeficiency virus, those unable to produce sputum samples or with extrapulmonary TB, household contacts, and children-should be considered. Studies beyond diagnostic accuracy that evaluate feasibility and population-level impacts are also needed. A biomarker-based diagnostic may be critical to ending the TB epidemic, but requires appropriate validation before implementation.


Subject(s)
Biological Assay , Diagnostic Tests, Routine/standards , Mycobacterium tuberculosis/isolation & purification , Practice Guidelines as Topic , Tuberculosis, Pulmonary/diagnosis , Adult , Biomarkers/blood , Biomarkers/urine , Blood Culture/standards , Child , Cohort Studies , Cross-Sectional Studies , Exhalation , Humans , Mycobacterium tuberculosis/pathogenicity , Mycobacterium tuberculosis/physiology , Reference Standards , Research Design , Saliva/chemistry , Saliva/microbiology , Sensitivity and Specificity , Sputum/microbiology , Tuberculosis, Pulmonary/microbiology , World Health Organization
4.
Nature ; 550(7677): 464, 2017 10 25.
Article in English | MEDLINE | ID: mdl-29072266
5.
J Magn Reson Imaging ; 45(1): 42-50, 2017 01.
Article in English | MEDLINE | ID: mdl-27251647

ABSTRACT

PURPOSE: To characterize the distribution of bone marrow fat in hip osteoarthritis (OA) using magnetic resonance imaging (MRI) and to assess its use as a potential biomarker. MATERIALS AND METHODS: In all, 67 subjects (39 female, 28 male) with either total hip replacement (THA) or different severities of radiographic OA, assessed by Kellgren-Lawrence grading (KLG), underwent 3T MRI of the pelvis using the IDEAL sequence to separate fat and water signals. Six regions of interest (ROIs) were identified within the proximal femur. Within each ROI the fractional-fat distribution, represented by pixel intensities, was described by its mean, standard deviation, skewness, kurtosis, and entropy. RESULTS: Hips were graded: 12 as severe symptomatic (THA), 33 had KLG0 or 1, 9 were KLG2, 11 with KLG3, and 2 with KLG4 were analyzed together. The fractional-fat content in the whole proximal femur did not vary with severity in males (mean (SD) 91.2 (6.0)%) but reduced with severity in females from 89.1 (6.7)% (KLG0,1), 91.5 (2.9)% (KLG2), 85.8 (16.7)% (KLG3,4) to 77.5 (11.9)% (THA) (analysis of variance [ANOVA] P = 0.029). These differences were most pronounced in the femoral head, where mean values fell with OA severity in both sexes from 97.9% (2.5%) (KLG0,1) to 73.0% (25.9%) (THA, P < 0.001) with the largest difference at the final stage. The standard deviation and the entropy of the distribution both increased (P < 0.001). CONCLUSION: Descriptors of the fractional fat distribution varied little with the severity of OA until the most severe stage, when changes appeared mainly in the femoral head, and have, therefore, limited value as biomarkers. LEVEL OF EVIDENCE: 2 J. Magn. Reson. Imaging 2017;45:42-50.


Subject(s)
Adipose Tissue/diagnostic imaging , Adiposity , Bone Marrow/diagnostic imaging , Magnetic Resonance Imaging/methods , Osteoarthritis, Hip/diagnostic imaging , Adipose Tissue/pathology , Adult , Aged , Aged, 80 and over , Biomarkers , Bone Marrow/pathology , Female , Humans , Male , Middle Aged , Osteoarthritis, Hip/pathology , Reproducibility of Results , Sensitivity and Specificity
7.
Nature ; 526(7575): 646, 2015 Oct 29.
Article in English | MEDLINE | ID: mdl-26511576
8.
J Exp Med ; 212(11): 1759-69, 2015 Oct 19.
Article in English | MEDLINE | ID: mdl-26458772

ABSTRACT

The world is in need of more effective approaches to controlling tuberculosis. The development of improved control strategies has been hampered by deficiencies in the tools available for detecting Mycobacterium tuberculosis and defining the dynamic consequences of the interaction of M. tuberculosis with its human host. Key needs include a highly sensitive, specific nonsputum diagnostic; biomarkers predictive of responses to therapy; correlates of risk for disease development; and host response-independent markers of M. tuberculosis infection. Tools able to sensitively detect and quantify total body M. tuberculosis burden might well be transformative across many needed use cases. Here, we review the current state of the field, paying particular attention to needed changes in experimental paradigms that would facilitate the discovery, validation, and development of such tools.


Subject(s)
Tuberculosis/prevention & control , Biomarkers , Humans , Interferon Type I/physiology , Sputum/microbiology , Tuberculosis/diagnosis , Tuberculosis/drug therapy , Tuberculosis/microbiology
9.
PLoS One ; 10(6): e0129470, 2015.
Article in English | MEDLINE | ID: mdl-26076167

ABSTRACT

Gene expression and functional studies have indicated that the molecular programmes involved in prostate development are also active in prostate cancer. PTEN has been implicated in human prostate cancer and is frequently mutated in this disease. Here, using the Nkx3.1:Cre mouse strain and a genetic deletion approach, we investigate the role of Pten specifically in the developing mouse prostate epithelia. In contrast to its role in other developing organs, this gene is dispensable for the initial developmental processes such as budding and branching. However, as cytodifferentiation progresses, abnormal luminal cells fill the ductal lumens together with augmented epithelial proliferation. This phenotype resembles the hyperplasia seen in postnatal Pten deletion models that develop neoplasia at later stages. Consistent with this, gene expression analysis showed a number of genes affected that are shared with Pten mutant prostate cancer models, including a decrease in androgen receptor regulated genes. In depth analysis of the phenotype of these mice during development revealed that loss of Pten leads to the precocious differentiation of epithelial cells towards a luminal cell fate. This study provides novel insight into the role of Pten in prostate development as part of the process of coordinating the differentiation and proliferation of cell types in time and space to form a functional organ.


Subject(s)
Cell Differentiation/genetics , Epithelial Cells/cytology , PTEN Phosphohydrolase/physiology , Prostate/embryology , Animals , Antigens, Neoplasm/metabolism , Biomarkers/metabolism , Cell Adhesion Molecules/metabolism , Cluster Analysis , Clusterin/metabolism , Gene Deletion , Male , Mice , PTEN Phosphohydrolase/genetics , PTEN Phosphohydrolase/metabolism , Prostate/cytology , Signal Transduction
10.
J Pharmacol Exp Ther ; 351(2): 259-69, 2014 11.
Article in English | MEDLINE | ID: mdl-25125580

ABSTRACT

The transient receptor potential (subfamily M, member 8; TRPM8) is a nonselective cation channel localized in primary sensory neurons, and is a candidate for cold thermosensing, mediation of cold pain, and bladder overactivity. Studies with TRPM8 knockout mice and selective TRPM8 channel blockers demonstrate a lack of cold sensitivity and reduced cold pain in various rodent models. Furthermore, TRPM8 blockers significantly lower body temperature. We have identified a moderately potent (IC50 = 103 nM), selective TRPM8 antagonist, PF-05105679 [(R)-3-[(1-(4-fluorophenyl)ethyl)(quinolin-3-ylcarbonyl)amino]methylbenzoic acid]. It demonstrated activity in vivo in the guinea pig bladder ice water and menthol challenge tests with an IC50 of 200 nM and reduced core body temperature in the rat (at concentrations >1219 nM). PF-05105679 was suitable for acute administration to humans and was evaluated for effects on core body temperature and experimentally induced cold pain, using the cold pressor test. Unbound plasma concentrations greater than the IC50 were achieved with 600- and 900-mg doses. The compound displayed a significant inhibition of pain in the cold pressor test, with efficacy equivalent to oxycodone (20 mg) at 1.5 hours postdose. No effect on core body temperature was observed. An unexpected adverse event (hot feeling) was reported, predominantly periorally, in 23 and 36% of volunteers (600- and 900-mg dose, respectively), which in two volunteers was nontolerable. In conclusion, this study supports a role for TRPM8 in acute cold pain signaling at doses that do not cause hypothermia.


Subject(s)
Pain/metabolism , TRPM Cation Channels/antagonists & inhibitors , TRPM Cation Channels/metabolism , Animals , Body Temperature/drug effects , Cold Temperature , Cross-Over Studies , Double-Blind Method , Guinea Pigs , HEK293 Cells , Humans , Male , Membrane Transport Modulators/pharmacology , Oxycodone/pharmacology , Pain/drug therapy , Rats , Rats, Wistar
11.
Eur J Pharmacol ; 740: 398-409, 2014 Oct 05.
Article in English | MEDLINE | ID: mdl-25058909

ABSTRACT

Patients with overactive bladder often exhibit abnormal bladder contractions in response to intravesical cold saline (positive ice-water test). The molecular entity involved in cold sensation within the urinary bladder is unknown, but a potential candidate is the ion channel, transient receptor potential (melastatin)-8 (TRPM8). The objective of the present study was to investigate the role of TRPM8 in a bladder-cooling reflex evoked in anaesthetised guinea-pigs that is comparable to the positive ice-water test seen in patients. Guinea-pig TRPM8 was cloned from L6 dorsal root ganglia (DRG) and expressed in HEK293 cells. Functional agonist- and cold-induced Ca2+ influx and electrophysiology assays were performed in these cells, and for comparison in HEK293 cells expressing human TRPM8, using a novel TRPM8 antagonist, the S-enantiomer of 1-phenylethyl 4-(benzyloxy)-3-methoxybenzyl (2-aminoethyl) carbamate hydrochloride (PBMC). Potency data from these assays was used to calculate intravenous infusion protocols for targeted plasma concentrations of PBMC in studies on micturition reflexes evoked by intravesical infusion of menthol or cold saline in anaesthetised guinea-pigs. Tissue expression of TRPM8 in guinea-pig bladder, urethra and in dorsal root ganglia neurones traced from the bladder was also investigated. TRPM8 mRNA and protein were detected in L6 dorsal root ganglia, bladder urothelium and smooth muscle. PBMC antagonised in vitro activation of human and guinea-pig TRPM8 and reversed menthol and cold-induced facilitation of the micturition reflex at plasma concentrations consistent with in vitro potencies. The present data suggest that the bladder-cooling reflex in the guinea-pig involves TRPM8. The potential significance of TRPM8 in bladder disease states deserves future investigation.


Subject(s)
TRPM Cation Channels/antagonists & inhibitors , Anilides/pharmacology , Animals , Body Temperature Regulation , Carbamates/pharmacology , Female , Ganglia, Spinal/metabolism , Guinea Pigs , HEK293 Cells , Humans , Male , Menthol/analogs & derivatives , Menthol/pharmacology , Muscle, Smooth/metabolism , Neurons/metabolism , TRPM Cation Channels/agonists , TRPM Cation Channels/genetics , TRPM Cation Channels/physiology , Urethra/metabolism , Urinary Bladder/metabolism
12.
Development ; 139(24): 4561-70, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23136395

ABSTRACT

Adrenal and gonadal steroids are essential for life and reproduction. The orphan nuclear receptor SF1 (NR5A1) has been shown to regulate the expression of enzymes involved in steroid production in vitro. However, the in vivo role of this transcription factor in steroidogenesis has not been elucidated. In this study, we have generated steroidogenic-specific Cre-expressing mice to lineage mark and delete Sf1 in differentiated steroid-producing cells of the testis, the ovary and the adrenal gland. Our data show that SF1 is a regulator of the expression of steroidogenic genes in all three organs. In addition, Sf1 deletion leads to a radical change in cell morphology and loss of identity. Surprisingly, sexual development and reproduction in mutant animals were not compromised owing, in part, to the presence of a small proportion of SF1-positive cells. In contrast to the testis and ovary, the mutant adult adrenal gland showed a lack of Sf1-deleted cells and our studies suggest that steroidogenic adrenal cells during foetal stages require Sf1 to give rise to the adult adrenal population. This study is the first to show the in vivo requirements of SF1 in steroidogenesis and provides novel data on the cellular consequences of the loss of this protein specifically within steroid-producing cells.


Subject(s)
Adrenal Glands/metabolism , DNA-Binding Proteins/physiology , Gonadal Steroid Hormones/metabolism , Ovary/metabolism , Testis/metabolism , Transcription Factors/physiology , Adrenal Glands/cytology , Adrenal Glands/embryology , Adrenal Glands/growth & development , Animals , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Cholesterol Side-Chain Cleavage Enzyme/genetics , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Embryo, Mammalian , Female , Gene Deletion , Integrases/genetics , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Male , Mice , Mice, Transgenic , Ovary/cytology , Ovary/embryology , Ovary/growth & development , RNA Splicing Factors , Testis/cytology , Testis/embryology , Testis/growth & development , Transcription Factors/genetics , Transcription Factors/metabolism , Transgenes/genetics
13.
Development ; 139(18): 3456-66, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22912418

ABSTRACT

The thymus and parathyroid glands are derived from the third pharyngeal pouch endoderm. The mechanisms that establish distinct molecular domains in the third pouch and control the subsequent separation of these organ primordia from the pharynx are poorly understood. Here, we report that mouse embryos that lack two FGF feedback antagonists, Spry1 and Spry2, display parathyroid and thymus hypoplasia and a failure of these organ primordia to completely separate from the pharynx. We show that FGF ligands and downstream reporter genes are expressed in highly regionalised patterns in the third pouch and that sprouty gene deletion results in upregulated FGF signalling throughout the pouch endoderm. As a consequence, the initiation of markers of parathyroid and thymus fate is altered. In addition, a normal apoptotic programme that is associated with the separation of the primordia from the pharynx is disrupted, resulting in the maintenance of a thymus-pharynx attachment and a subsequent inability of the thymus to migrate to its appropriate position above the heart. We demonstrate that the sprouty genes function in the pharyngeal endoderm itself to control these processes and that the defects in sprouty-deficient mutants are, at least in part, due to hyper-responsiveness to Fgf8. Finally, we provide evidence to suggest that parathyroid hypoplasia in these mutants is due to early gene expression defects in the third pouch, whereas thymus hypoplasia is caused by reduced proliferation of thymic epithelial cells in the thymus primordium.


Subject(s)
Fibroblast Growth Factors/metabolism , Parathyroid Glands/embryology , Parathyroid Glands/metabolism , Animals , Endoderm/metabolism , Fibroblast Growth Factors/genetics , Gene Expression Regulation, Developmental/genetics , Gene Expression Regulation, Developmental/physiology , Immunohistochemistry , In Situ Hybridization , Mice , Signal Transduction , Thymus Gland/embryology , Thymus Gland/metabolism
14.
Dev Dyn ; 241(8): 1310-24, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22674535

ABSTRACT

BACKGROUND: 22q11.2 deletion syndrome (22q11DS) is the most common microdeletion syndrome in humans, characterized by cardiovascular defects such as interrupted aortic arch, outflow tract defects, thymus and parathyroid hypo- or aplasia, and cleft palate. Heterozygosity of Tbx1, the mouse homolog of the candidate TBX1 gene, results in mild defects dependent on genetic background, whereas complete inactivation results in severe malformations in multiple tissues. RESULTS: The loss of function of two Sprouty genes, which encode feedback antagonists of receptor tyrosine kinase (RTK) signaling, phenocopy many defects associated with 22q11DS in the mouse. The stepwise reduction of Sprouty gene dosage resulted in different phenotypes emerging at specific steps, suggesting that the threshold up to which a given developmental process can tolerate increased RTK signaling is different. Tbx1 heterozygosity significantly exacerbated the severity of all these defects, which correlated with a substantial increase in RTK signaling. CONCLUSIONS: Our findings suggest that TBX1 functions as an essential component of a mechanism that protects the embryo against perturbations in RTK signaling that may lead to developmental defects characteristic of 22q11DS. We propose that genetic factors that enhance RTK signaling ought to be considered as potential genetic modifiers of this syndrome.


Subject(s)
Receptor Protein-Tyrosine Kinases/metabolism , T-Box Domain Proteins/metabolism , Alleles , Animals , Gene Expression Regulation, Developmental/genetics , Gene Expression Regulation, Developmental/physiology , In Situ Hybridization , Magnetic Resonance Imaging , Mice , Mice, Knockout , Mice, Mutant Strains , Real-Time Polymerase Chain Reaction , Receptor Protein-Tyrosine Kinases/genetics , Signal Transduction , T-Box Domain Proteins/genetics
15.
Eur J Pharmacol ; 682(1-3): 142-52, 2012 May 05.
Article in English | MEDLINE | ID: mdl-22374259

ABSTRACT

Central and peripheral 5-hydroxytryptamine (5-HT) receptors play a critical role in the regulation of micturition. Bolus doses of 5-HT(2A/2C) receptor agonists have been shown to activate the external urethral sphincter (EUS) and to inhibit micturition. This study was designed to determine the contribution of these two 5-HT receptor subtypes to activation of the EUS and inhibition of micturition utilising pharmacokinetic knowledge to better control drug exposure. Recordings of urethral and bladder pressure, EUS-Electromyogram (EMG), the micturition reflex induced by bladder filling, blood pressure and heart rate were made in anaesthetized female rats. The effects of intravenous (i.v.) infusions of the 5-HT(2) receptor agonist (2S)-1-(6-chloro-5-fluoroindol-1-yl)propan-2-amine fumarate (Ro 60-0175) in the absence or presence of the selective 5-HT(2C) receptor antagonist 6-chloro-5-methyl-N-[6-(2-methylpyridin-3-yl)oxypyridin-3-yl]-2,3-dihydroindole-1-carboxamide dihydrochloride (SB 242084) or 5-HT(2A) receptor antagonist (R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol (MDL-100,907) were studied on these variables. Continuous infusion of increasing concentrations of Ro 60-0175 only evoked EUS-EMG activity at the highest concentration, which was blocked by co-infusion of MDL-100,907 but not SB 242084. Urethral pressure was unaffected by any drug infusion. Ro 60-0175 at the lowest concentration inhibited the micturition reflex but as the concentration increased this was reversed to facilitation. SB 242084 blocked the inhibition while MDL-100,907 blocked the excitation. Activation of 5-HT(2A) not 5-HT(2C) receptors evoked EUS-EMG activity. In conclusion, 5-HT(2A) receptor activation facilitated the micturition reflex and evoked EUS-EMG while 5-HT(2C) receptor activation only inhibited the micturition reflex.


Subject(s)
Muscle, Skeletal/metabolism , Receptor, Serotonin, 5-HT2A/metabolism , Receptor, Serotonin, 5-HT2C/metabolism , Serotonin 5-HT2 Receptor Antagonists/pharmacokinetics , Urethra/metabolism , Urination/drug effects , Anesthesia , Animals , Blood Pressure/drug effects , Drug Interactions , Electromyography , Female , Muscle, Skeletal/drug effects , Muscle, Skeletal/physiology , Rats , Serotonin 5-HT2 Receptor Antagonists/administration & dosage , Serotonin 5-HT2 Receptor Antagonists/pharmacology , Urethra/drug effects , Urethra/physiology
16.
Mol Cell Endocrinol ; 351(1): 12-8, 2012 Mar 31.
Article in English | MEDLINE | ID: mdl-22024498

ABSTRACT

SF-1 is a master regulator of steroidogenesis whose expression is critical for normal adrenal and gonadal organogenesis. Strict maintenance of SF-1 levels is essential, and mutations causing under- or overexpression result in congenital adrenal and gonadal defects or hyperplasia, respectively. Data from transgenic mouse models points to a network of transcription factors responsible for stringent regulation of Sf-1 expression during development, which bind to intronic enhancer elements in addition to the basal promoter to specifically modulate transcription in each Sf-1-expressing tissue. Furthermore, analysis of the role of SF-1 in adrenal tumourigenesis implies that improper developmental regulation of Sf-1 expression may have postnatal consequences separate from the well-documented developmental defects.


Subject(s)
Adrenal Gland Neoplasms/metabolism , Adrenal Glands/metabolism , Cell Transformation, Neoplastic/metabolism , Enhancer Elements, Genetic , Gene Expression Regulation, Neoplastic , Steroidogenic Factor 1/metabolism , Adrenal Gland Neoplasms/genetics , Adrenal Gland Neoplasms/pathology , Adrenal Glands/embryology , Adrenal Glands/pathology , Animals , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/pathology , Humans , Hyperplasia , Introns , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , Steroidogenic Factor 1/genetics
17.
J Pharmacol Toxicol Methods ; 55(2): 184-92, 2007.
Article in English | MEDLINE | ID: mdl-16905339

ABSTRACT

INTRODUCTION: In patients with detrusor hyperreflexia, intravesical instillation of ice-cold water results in the development of involuntary bladder contractions at volumes less than normal cystometric capacity. This is referred to as a positive ice-water test (+IWT) and can be reversed by vanilloid receptor agonists and potentiated by menthol. The present study was designed to investigate the existence of an analogous cooling reflex in the guinea-pig bladder that could be used as a small animal model in order to test the effects of drugs on the reflex. METHODS: Bladder pressure and external urethral sphincter electromyogram (EUS EMG) were recorded in alpha-chloralose/urethane anaesthetised guinea-pigs during rapid infusion of cold or warm saline into the bladder with or without prior intravesical exposure to menthol or resiniferatoxin (RTX). RESULTS: The mean control micturition threshold volume (TV) of 2.58 ml at 38 degrees C was reduced to 1.52 ml in response to saline infusion at 3 degrees C (P=0.001). The cold-induced reduction in TV was reproducible during several subsequent repeat infusions at 38 degrees C and 3 degrees C and was accompanied by decreases in bladder voiding pressure. The duration of the micturition reflex was markedly increased following cold compared with warm saline infusion (mean 24.5 s at 3 degrees C, 10.2 s at 38 degrees C, P=0.001) and was associated with oscillations in bladder pressure and concomitant bursting activity in the EUS EMG. During step-wise decreases in infusate temperature from 38 degrees C to 23 degrees C, 15 degrees C, 7 degrees C and 3 degrees C, the threshold infusate temperature to elicit a significant reduction in TV was 15 degrees C. The reduction in TV at 3 degrees C was potentiated by intravesical infusion of 0.6 mM menthol whilst intravesical infusion of 500 nM RTX reversed the reduction in TV at 3 degrees C. DISCUSSION: These data suggest that a bladder-cooling reflex is present in the anaesthetised guinea-pig and represents a useful small animal model of the clinical +IWT.


Subject(s)
Anesthesia , Disease Models, Animal , Muscle Contraction/physiology , Reflex/physiology , Urinary Bladder/physiology , Water , Animals , Cold Temperature , Diterpenes/pharmacology , Electromyography/methods , Female , Guinea Pigs , Menthol/pharmacology , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Muscle, Smooth/physiology , Sodium Chloride/administration & dosage , Sodium Chloride/pharmacology , Temperature , Urinary Bladder/drug effects , Urinary Bladder/innervation , Urination/drug effects , Urination/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...